Prudential Financial Inc Cyma Bay Therapeutics, Inc. Transaction History

Prudential Financial Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$12.63 - $24.47 $101,747 - $197,130	-8,056 Reduced 3.33%	233,921 $5.53 Million
Q3 2023 Nov 13, 2023	BUY	$10.86 - $17.62 $9,415 - $15,276	867 Added 0.36%	241,977 $3.61 Million
Q2 2023 Aug 11, 2023	BUY	$7.47 - $10.95 $1.8 Million - $2.64 Million	241,110 New	241,110 $2.64 Million

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.